Chemotherapy for triple-negative breast cancer (TNBC) typically lasts about 16 to 24 weeks for early-stage disease, though the total treatment timeline can stretch longer when immunotherapy or additional oral chemotherapy is added after surgery. The exact duration depends on whether chemo is given before surgery (neoadjuvant), after surgery (adjuvant), or for metastatic disease, where treatment continues indefinitely as long as it’s working.
Neoadjuvant Chemotherapy: 16 to 24 Weeks Before Surgery
Most people with early-stage TNBC receive chemotherapy before surgery to shrink the tumor and gauge how well the cancer responds. This neoadjuvant phase is the core of treatment and typically follows a two-part structure: a taxane-based phase followed by an anthracycline-based phase.
The most common approach starts with 12 weekly infusions of paclitaxel (a taxane), often combined with a platinum drug like carboplatin. This first block takes about 12 weeks. After that, you move into four cycles of an anthracycline plus cyclophosphamide combination, given either every two weeks (dose-dense) or every three weeks. On a dose-dense schedule, those four cycles take 8 weeks. On a standard every-three-week schedule, they take 12 weeks.
That means the full neoadjuvant chemo phase runs roughly 20 weeks on a dose-dense schedule or 24 weeks on a standard schedule. Some protocols are shorter. A trial at Tata Memorial Hospital used only 8 weeks of paclitaxel before four cycles of the anthracycline combination, compressing the total timeline. The GeparSixto study used an 18-week regimen. Your oncologist will choose a schedule based on tumor size, lymph node involvement, and how aggressive the cancer appears.
When Immunotherapy Is Added
For most early-stage TNBC patients today, an immunotherapy drug called pembrolizumab is added to the chemotherapy regimen. This follows the protocol established in the KEYNOTE-522 trial, which showed significantly better outcomes when immunotherapy was layered on top of chemo.
In this approach, pembrolizumab is given every three weeks alongside chemo during the entire neoadjuvant phase, adding no extra weeks to the chemo timeline itself. The immunotherapy infusion happens on the same day as your chemo visits. The neoadjuvant portion still runs about 24 weeks (four cycles with the taxane/carboplatin, then four cycles with the anthracycline combination).
The key difference is what happens after surgery. Pembrolizumab continues for nine additional cycles post-surgery, given every three weeks. That’s another 27 weeks, or roughly six to seven months. So when immunotherapy is part of the plan, the total active treatment timeline from first infusion to last can approach a full year, even though the chemotherapy portion wraps up before surgery.
After Surgery: Possible Additional Treatment
Surgery typically happens three to six weeks after the last neoadjuvant chemo cycle. What comes next depends on how the tumor responded.
If pathology shows no remaining cancer cells (a pathologic complete response), post-surgical treatment may involve only the remaining pembrolizumab cycles. But if cancer cells are still present in the surgical specimen, an oral chemotherapy drug called capecitabine is often prescribed. This is taken as a pill twice daily for two weeks, followed by a one-week break, repeated for six to eight cycles. At six cycles, that adds another 18 weeks of treatment. At eight cycles, it’s 24 weeks.
This means patients with residual disease face the longest total treatment window: roughly 5 to 6 months of neoadjuvant chemo, surgery, then 4 to 6 months of oral chemo and/or immunotherapy afterward.
Dose-Dense vs. Standard Scheduling
The spacing between cycles has a real impact on how quickly you finish treatment. Dose-dense scheduling compresses the anthracycline portion by giving infusions every two weeks instead of every three, supported by injections that boost white blood cell counts between cycles. This shaves about four weeks off the total chemo timeline.
Dose-dense scheduling does mean more frequent clinic visits in a shorter window, which can feel more intense. Side effects like fatigue and low blood counts may peak harder. But the shorter overall duration appeals to many patients, and outcomes are at least as good. When pembrolizumab is part of the plan, dose-dense scheduling creates some logistical complexity because the immunotherapy runs on a three-week cycle while chemo runs on a two-week cycle, meaning you may have extra infusion visits where only one drug is given.
Metastatic TNBC: No Fixed Endpoint
When TNBC has spread to other organs, the treatment timeline is fundamentally different. There’s no set number of cycles or weeks. Chemotherapy continues as long as it controls the disease and side effects remain manageable. Treatment stops or switches to a different regimen when the cancer progresses or toxicity becomes too great.
Patients with metastatic TNBC receive an average of about 2.7 lines of chemotherapy over the course of their treatment, though the range is wide, from one to nine. Each “line” is a different drug or combination tried when the previous one stops working. Research on platinum-based regimens found that patients who received two or more lines of platinum-based chemo had a median overall survival of about 25 months, compared to 17 months for those who received fewer. The timing of when platinum drugs are introduced, whether first-line or later, didn’t significantly change outcomes.
What the Full Timeline Looks Like
Putting it all together for early-stage TNBC with the current standard of care:
- Neoadjuvant chemo plus immunotherapy: approximately 20 to 24 weeks
- Surgery: 3 to 6 weeks after last chemo cycle
- Post-surgery immunotherapy: 9 cycles over about 27 weeks
- Oral chemo (if residual disease): 18 to 24 additional weeks
From first infusion to final treatment, the entire process spans roughly 10 to 14 months for most early-stage patients. The chemotherapy itself, meaning the IV drugs that cause the most familiar side effects like hair loss and nausea, is concentrated in that initial 5- to 6-month neoadjuvant window. Everything after surgery tends to be more tolerable, though not without its own side effects. The oral chemo can cause hand-foot syndrome and digestive issues, and immunotherapy can trigger inflammatory reactions in various organs.
Your oncologist will map out a specific calendar at the start of treatment, but flexibility is built in. Cycles sometimes get delayed by a week if blood counts are too low or side effects need time to resolve. Most people should expect their actual timeline to run a few weeks longer than the textbook schedule.